Cardiff selloff brings attractive entry point, says H.C. Wainwright

H.C. Wainwright says the “market overreaction” in shares of Cardiff Oncology (CRDF) “provides an attractive stock price entry point.” Cardiff announced that it will now share updated clinical data from the CRDF-004 trial on July 29, as opposed to the prior guidance of the first half of 2025, driving an after-hours selloff of 13%, the analyst tells investors in a research note. H.C. Wainwright notes that during its discussion with management yesterday, the company disclosed the rationale for this slight delay is that the majority of the enrolled patients shall have at least two post-baseline scans by this time point. “This is a prudent and investor-conscious decision since it provides a more robust dataset and potentially removes the concern of unconfirmed responses,” the firm contends. It reiterates a Buy rating on the shares with an $18 price target